Changes in eosinophil count during bacterial infection: revisiting an old marker to assess the efficacy of antimicrobial therapy

Davido, Benjamin; Makhloufi, S.; Matt, Morgan; Câlin, Ruxandra; Sénard, Olivia; Perronne, C.; Dinh, Aurélien; Salomon, Jérôme

doi:10.1016/j.ijid.2017.06.005

Cited by 39 publications

(37 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar to previous results [14,[16][17][18], we found a sustained eosinopenic response in nonsurvivors, while the median eosinophil count in survivors tended to quickly rise to normal levels within days. The value of eosinophil count in predicting response to antibiotic therapy was recently reported [20]. However, significant overlap of EC was noted between survivors and non-survivors in our study and persistent eosinopenia for several days was not uncommon in survivors (e.g.…”

Section: Ec As a Monitoring Parametersupporting

confidence: 38%

“…Similarly, Terradas et al [17] found that sustained eosinopenia (< 45/µL) in patients with bacteremia was an independent risk factor for mortality, while in survivors' eosinophil counts tend to return to normal levels within 2-3 days. More recently monitoring the eosinophil count has been suggested as a marker of efficacy of antibiotic therapy [20][21][22].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Eosinophil count (EC) as a diagnostic and prognostic marker for infection in the internal medicine department setting

Karakonstantis

Gryllou

Papazoglou

et al. 2019

Romanian Journal of Internal Medicine

View full text Add to dashboard Cite

Introduction. Eosinopenia has been previously investigated as a marker to differentiate infectious from non-infectious diagnoses and as a prognostic marker. Most previous studies were conducted in intensive care unit patients. Our study focuses on the value of eosinopenia in patients admitted to the Internal Medicine department. Methods. We retrospectively analyzed 271 consecutive patients with infection and 31 patients presenting with fever or inflammatory syndrome and a non-infectious diagnosis. We evaluated and compared the following markers for differentiating infectious from non-infectious diagnoses: eosinophil count [EC], CRP, WBC and neutrophil-to-lymphocyte count ratio [NLCR]. We also evaluated the value of eosinopenia as a monitoring parameter in patients with infections. Results. Eosinopenia at admission was found in 71% of patients with infection compared to 32% in the non-infection group. EC and NLCR were moderate markers for discriminating infection from non-infection, with an area under the receiver operating characteristic curve of 0.789 and 0.718 respectively. Significant eosinopenia (≤ 10/µL) had a high specificity (90%) for diagnosing infections. High EC at admission (> 400/µL) was rare in the infection group (1.5%), but not uncommon in the non-infection group (25.8%). Persistent eosinopenia was noted in non-survivors, compared to the rapid normalization of EC in survivors. Conclusions. Among patients presenting with fever and/or high inflammatory markers a low EC is supportive of infection, while a high EC may suggest non-infectious diagnoses. The persistence/ resolution of eosinopenia may be a useful monitoring parameter to predict response to therapy.

show abstract

Section: Ec As a Monitoring Parametersupporting

confidence: 38%

Section: Introductionmentioning

confidence: 99%

Eosinophil count (EC) as a diagnostic and prognostic marker for infection in the internal medicine department setting

Karakonstantis

Gryllou

Papazoglou

et al. 2019

Romanian Journal of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…Nonclinical data support that eosinophils may be activated by, and have the ability to kill, certain bacteria, and eosinopenia has been described as a feature of modeled, acute bacterial infections [5,97,98]. In patients, an inverse relationship between bacterial load and peripheral blood eosinophils has been reported [99,100], and eosinopenia may predict a bacterial etiology for patients with sepsis [101]. Eosinophil degranulation products have been detected in respiratory secretions from patients during respiratory syncytial viral (RSV) infections [102], and eosinophil degranulation was associated with a more favorable outcome in mice infected with pneumonia virus of mice (PVM), a respiratory virus infection in mice similar to human RSV [103].…”

Section: Viral and Microbial Infectionmentioning

confidence: 99%

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab

Jackson

Korn²,

Mathur

et al. 2020

Drug Saf

View full text Add to dashboard Cite

Eosinophils play a pivotal role in the inflammatory pathology of asthma and have been the target of new biologic treatments for patients with eosinophilic asthma. Given the central role of interleukin (IL)-5 in the eosinophil lifecycle, several therapies directed against the IL-5 pathway have been developed, including the anti-IL-5 antibodies mepolizumab and reslizumab and the IL-5 receptor α (IL-5Rα)-directed cytolytic antibody benralizumab. Eosinophil-depleting therapies represent a relatively new class of asthma treatment, and it is important to understand their long-term efficacy and safety. Eosinophils have been associated with host protection and tumor growth, raising potential concerns about the consequences of long-term therapies that deplete eosinophils. However, evidence for these associations in humans is conflicting and largely indirect or based on mouse models. Substantial prospective clinical trial and postmarketing data have accrued, providing insight into the potential risks associated with eosinophil depletion. In this review, we explore the current safety profile of eosinophil-reducing therapies, with particular attention to the potential risks of malignancies and severe infections and a focus on benralizumab. Benralizumab is an IL-5Rα-directed cytolytic monoclonal antibody that targets and efficiently depletes blood and tissue eosinophils through antibody-dependent cell-mediated cytotoxicity. Benralizumab is intended to treat patients with severe, uncontrolled asthma with eosinophilic inflammation.

show abstract

“…Several studies evaluated the behaviour of eosinophils during acute bacterial infections, where eosinopenia has been shown to be a common feature [ 17 ]. During bacteremia, there is an inverse relationship between bacterial load and peripheral blood eosinophils [ 123 ] and eosinopenia was shown to be a reliable marker of bacterial aetiology in patients admitted with sepsis to the intensive care unit [ 124 – 126 ]. Finally, low eosinophil count was shown to be a risk factor for persistent diarrhoea or death and recurrent disease in patients with Clostridium difficile infection [ 127 ].…”

Section: Eosinophils In Infectious Diseasesmentioning

confidence: 99%

Eosinophils from Physiology to Disease: A Comprehensive Review

Ramirez

Yacoub

Ripa

et al. 2018

BioMed Research International

211

220

View full text Add to dashboard Cite

Despite being the second least represented granulocyte subpopulation in the circulating blood, eosinophils are receiving a growing interest from the scientific community, due to their complex pathophysiological role in a broad range of local and systemic inflammatory diseases as well as in cancer and thrombosis. Eosinophils are crucial for the control of parasitic infections, but increasing evidence suggests that they are also involved in vital defensive tasks against bacterial and viral pathogens including HIV. On the other side of the coin, eosinophil potential to provide a strong defensive response against invading microbes through the release of a large array of compounds can prove toxic to the host tissues and dysregulate haemostasis. Increasing knowledge of eosinophil biological behaviour is leading to major changes in established paradigms for the classification and diagnosis of several allergic and autoimmune diseases and has paved the way to a “golden age” of eosinophil-targeted agents. In this review, we provide a comprehensive update on the pathophysiological role of eosinophils in host defence, inflammation, and cancer and discuss potential clinical implications in light of recent therapeutic advances.

show abstract

Changes in eosinophil count during bacterial infection: revisiting an old marker to assess the efficacy of antimicrobial therapy

Cited by 39 publications

References 22 publications

Eosinophil count (EC) as a diagnostic and prognostic marker for infection in the internal medicine department setting

Eosinophil count (EC) as a diagnostic and prognostic marker for infection in the internal medicine department setting

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab

Eosinophils from Physiology to Disease: A Comprehensive Review

Contact Info

Product

Resources

About